

# **Gastrointestinal Diseases, Genetic Risk, and Incident Dementia: A Prospective Cohort**

## **Study in 352,463 Middle-Aged Adults**

**Running head:** Gastrointestinal diseases and dementia

Shuai Yuan<sup>1,2\*</sup>, Lintao Dan<sup>1\*</sup>, Yao Zhang<sup>3</sup>, Jing Wu<sup>4</sup>, Jianhui Zhao<sup>1</sup>, Jie Chen<sup>1#</sup>, Xue Li<sup>1#</sup>, Miia

Kivipelto<sup>5-9</sup>, Susanna C. Larsson<sup>2,10</sup>

## **Affiliations**

<sup>1</sup> Department of Big Data in Health Science, School of Public Health and The Second

Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

<sup>2</sup> Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine,

Karolinska Institutet, Stockholm, Sweden

<sup>3</sup> Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of

Medicine, Shanghai, China

<sup>4</sup> Aging Research Center, Department of Neurobiology, Care Sciences and Society,

Karolinska Institutet and Stockholm University, Stockholm, Sweden

<sup>5</sup> Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society,

Karolinska Institutet, Stockholm, Sweden

<sup>6</sup> Department of Public Health and Welfare, Population Health Unit, Finnish Institute for Health

and Welfare, Helsinki, Finland

<sup>7</sup> Ageing Epidemiology Research Unit, School of Public Health, Imperial College London,

London, United Kingdom

<sup>8</sup> Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio,

Finland

<sup>9</sup> Theme Aging, Karolinska University Hospital, Sweden

<sup>10</sup> Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

\*Shuai Yuan and Lintao Dan share joint first authorship

# **#Corresponding authors:**

Xue Li, Department of Big Data in Health Science, School of Public Health and The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, xue.li@ed.ac.uk;  
Jie Chen, Centre for Global Health, School of Public Health, Zhejiang University School of Medicine, Hangzhou, China, med\_chenjie@zju.edu.cn;

Word count abstract: 338

Word count manuscript: 2990

Numbers of tables / figures: 3/1

Numbers of supplementary tables / figures: 11/3

## **Key Points**

**Question:** Are the gastrointestinal diseases associated with risk of incident dementia?

**Findings:** This large-scaled prospective cohort study including 352,463 participants found that seven gastrointestinal diseases were associated with an increased risk of dementia. The associations of cirrhosis, irritable bowel syndrome, gastritis and duodenitis, gastroesophageal reflux disease, and peptic ulcer appeared to be more strongly associated with early-onset

dementia compared to late-onset dementia.

**Meaning:** Seven gastrointestinal diseases are associated with an increased risk of incident dementia and appeared to be stronger for early-onset dementia compared to late-onset dementia.

## Abstract

**Importance** Although gastrointestinal disease affects gut microbiota and their metabolites associated with dementia risk, the associations between gastrointestinal diseases and the risk of incident dementia are not established.

**Objective** To examine the associations between 14 gastrointestinal diseases and incident dementia.

**Design, setting, and participants** Cohort study. This cohort analysis included 352,463 participants free of baseline dementia. Participants joined the UK Biobank study from 2006 to 2010 and were followed up until 2018 or 2021.

**Exposures** Fourteen baseline gastrointestinal diseases were defined with data from inpatient, primary care, national cancer registries and self-reported data. Polygenic risk score (RPS) and apolipoprotein E (*APOE*) was constructed by individuals' genetic data.

**Main Outcomes and Measures:** Primary outcome was incident all-cause dementia ascertained via a inpatient, primary care, and national death registries. Secondary outcomes were risk of common subtypes of dementia, including Alzheimer's disease and vascular dementia as well as early-onset (i.e., with the onset age < 65 years) and late-onset (≥ 65 years) dementia by diagnosis age.

**Results** During a median follow-up of 12.4 years among 352,463 participants (mean [SD] age, 55.8 [8.1] years; 54.1% were women), 5648 incident dementia cases were diagnosed. Seven gastrointestinal diseases showed significant associations with an increased risk of dementia after controlling covariates and multiple testing. Compared to individuals without gastrointestinal diseases, the risk of dementia increased from 26% (95% confidence interval

13%-41%) for patients with intestinal diverticular disease to 121% (95% confidence interval 57%-211%) for patients with cirrhosis. The associations were different between certain gastrointestinal diseases and dementia by onset age. The associations appeared to be stronger for cirrhosis ( $P = 0.001$ ), irritable bowel syndrome ( $P < 0.001$ ), gastritis and duodenitis ( $P = 0.002$ ), gastroesophageal reflux disease ( $P < 0.001$ ), and peptic ulcer ( $P = 0.030$ ) with early-onset dementia. There were no multiplicative interactions for PRS or *APOE* ( $P > 0.05$ ).

**Conclusions and relevance** This study found associations of several gastrointestinal diseases with an increased risk of incident dementia, especially early-onset dementia. Our findings imply the great importance of dementia prevention among patients with gastrointestinal diseases.

## 1. Background

Due to the population aging, the number of patients with dementia keeps raising and is projected to increase to 152 million by 2050 worldwide.<sup>1</sup> The increasing prevalence of dementia has generated a tremendous adverse impact on individuals, their families, and the whole society, leading to an economic cost of approximately 1 trillion dollars annually.<sup>1</sup> Only a few potentially modifiable risk factors have been identified for dementia, such as low education level, traumatic brain injury, smoking, and possibly physical inactivity and air pollution<sup>1</sup>, and the etiological basis of the disease remains largely uncovered.<sup>2</sup> Thus, it is of urgency to explore other risk factors for dementia with the aims of deepening the understanding of the disease as well as identifying preventive measures.

With increasing data on omics, microbiome in particular, the gut-brain axis hypothesis of oronic communication between the central nervous system, the enteric nervous system, and gastrointestinal tract has been widely explored.<sup>3</sup> The development of dementia caused by damage to central nervous cells has been associated with the alteration of gut microbiota<sup>4,5</sup> and their related metabolites<sup>6-8</sup>. Gut microbiota and gastrointestinal disorders have mutual impacts;<sup>9,10</sup> thus, gastrointestinal disorders may also influence the risk of dementia.

Population-based observational studies have found an elevated risk of cognitive decline and dementia among patients with inflammatory bowel disease<sup>11</sup> and liver diseases<sup>12,13</sup> even though the evidence was inconsistent<sup>14</sup>. Another study observed that treatment with proton pump inhibitors (PPIs), which are widely used for gastrointestinal diseases, was associated with an increased risk of incident dementia.<sup>15</sup> Given conflicting and limited data as well as unknown associations for other gastrointestinal diseases, we conducted this study to

comprehensively investigate the associations of 14 gastrointestinal endpoints with the risk of dementia.

## **2. Methods**

### **2.1 Study Population**

This study leveraged data from the UK Biobank, which is an ongoing national prospective cohort project that enrolled over 500,000 individuals from in the UK between 2006 and 2010.<sup>16</sup> The UK Biobank study had been approved by the North West–Haydock Research Ethics Committee (REC reference: 21/NW/0157). All participants had signed an electronic consent. In this study, we excluded individuals with baseline dementia or those diagnosed with dementia in the first year of follow-up ( $n = 4852$ ), individuals who developed any studied gastrointestinal diseases after baseline ( $n = 124,454$ ), and individuals without genetic information ( $n = 20,721$ ). In total, 352,463 participants were included in the final analysis (**Supplementary Figure 1**). The study was conducted in accordance with the STROBE checklist.

### **2.2 Gastrointestinal Diseases**

The study focused on fourteen gastrointestinal diseases, including gastroesophageal reflux disease, gastritis and duodenitis, celiac disease, Crohn's disease, ulcerative colitis, intestinal diverticular disease, irritable bowel syndrome, peptic ulcer, pancreatitis (acute and chronic pancreatitis), gallbladder and biliary diseases (cholangitis, cholecystitis, and cholelithiasis), non-alcoholic fatty liver disease, chronic liver cirrhosis, appendicitis, and overall gastrointestinal cancer (esophageal, gastric, small intestinal, colorectal, pancreatic, gallbladder, and hepatic cancers). These gastrointestinal outcomes were ascertained by

diagnostic codes from nationwide inpatient dataset, primary care dataset, cancer registries, and self-report diagnosis reviewed by nurses. Detailed diagnostic codes are displayed in **Supplementary Table 1 and 2**. The accuracy of these diagnostic codes has been found to be high (>89%) in the annual report by the Audit Commission for Local Authorities the National Health Service in England and Wales.<sup>17</sup>

### **2.3 Ascertainment of Dementia**

Similarly, the incident dementia was ascertained by diagnostic codes from inpatient dataset, primary care dataset, and death registries. Self-reported dementia diagnosis was used to identify and remove individuals with baseline dementia. The diagnostic codes for all-cause dementia had been used in previous studies and shown to be valid (**Supplementary Table 3**).<sup>18</sup> To differentiate the etiology of dementia subtypes,<sup>19</sup> two common subtypes, Alzheimer's disease and vascular dementia, were defined using diagnostic codes shown in **Supplementary Table 3**. We also classified dementia into early-onset (i.e., with the onset age < 65 years) and late-onset ( $\geq$  65 years) dementia by diagnosis age.

### **2.4 Polygenic Risk Score (PRS) and Apolipoprotein E (APOE)**

We constructed a PRS for dementia based on 39 well-established genetic variants<sup>20</sup> from large-scaled genome-wide association analyses on Alzheimer's disease<sup>21-23</sup>. The PRS was generated by multiplying the genotype dosage of each risk allele for each variant by its respective weight and then summing across all variants. The weights given for the score were derived from International Genomics of Alzheimer's Project (IGAP) studies.<sup>22,24</sup> Details of used genetic variants are presented in the **Supplementary Table 4**. Of note, *APOE* gene was not included in the PRS.



The *APOE* haplotypes ( $\epsilon 2/\epsilon 3/\epsilon 4$ ) were genotyped and determined by 2 genetic variants (i.e., rs429358 and rs7412). Participants with 1 or 2  $\epsilon 4$  alleles were defined as *APOE*  $\epsilon 4$  carriers and otherwise as *APOE*  $\epsilon 4$  noncarriers.

## **2.5 Assessment of Covariates**

We collected information on age at recruitment, sex, educational attainment, smoking status, alcohol consumption, physical activity, and family history of dementia from the baseline questionnaires. Body mass index (BMI) were measured by trained nurses at clinical visits. Diet quality was assessed by a dementia-associated healthy diet score with data from food frequency questionnaires.<sup>25</sup> The Townsend deprivation index was constructed as a complex indicator of socioeconomic status using the method instructed online (<https://biobank.ndph.ox.ac.uk/showcase/label.cgi?id=76>). History of hypertension, stroke, and depression were defined by data from the self-reported questionnaires, electronic health-related records, drug prescription, and baseline blood pressure measurement. Regular use of PPIs was recorded in a verbal interview by trained nurses. If covariate information was missing, we applied single imputation method by imputing the median values for continuous variables or applied a most frequently used category for categorical variables (the highest missing rate among covariates was 4.9%). Detailed information and definition of covariates are presented in **Supplementary Table 5**.

## **2.6 Statistical Analysis**

The Student's t-test and chi-square test was used to examine the differences in baseline characteristics by incident disease status for continuous and categorical variables, respectively. Treating age as timescale, the Cox proportional hazard regression was used to

estimate the associations of gastrointestinal diseases with the risk of incident dementia and its subtypes. Three models were performed: 1) model 1 adjusted for age and sex; 2) model 2 additionally adjusted for Townsend deprivation index, educational attainment, BMI, physical activity, diet, smoking status, alcohol consumption, baseline hypertension, and baseline stroke; and 3) model 3 further adjusted for PRS. The proportionality of hazards assumption was examined using the Schoenfeld residuals method and found to be satisfied ( $P > 0.11$ ). We examined the associations of gastrointestinal diseases with the risk of dementia subtypes. Heterogeneity between disease subtypes was calculated using the contrast test method.<sup>26</sup> We calculated the multiplicative interaction and further performed stratification analysis for PRS categories, *APOE*  $\epsilon 4$  carrying status, sex, and educational attainment.<sup>25</sup> To examine the robustness of the results, we performed several sensitivity analyses: 1) the analysis further adjusted for baseline depression; 2) the analysis further adjusted for family history of dementia; 3) the analysis excluding incident cases diagnosed in the first 3 years of follow-up; 4) the analysis including individuals who developed incident gastrointestinal diseases, and 5) the analysis excluding participants with incident Parkinson's disease, a major neurodegeneration disease. Given PPIs are routinely used among patients with gastrointestinal diseases and has been associated with dementia,<sup>15</sup> we also performed a sensitivity analysis with further adjustment for PPI use. To rule out the influence of competing risk, we performed a competing risk model to account for the competing risk of death using R package "cmprsk". We corrected for multiple comparisons with the false discovery rate (FDR) method. All statistical analyses were conducted using R 4.1.2. Two-sided FDR-adjusted  $P$  value (Q value)  $< 0.05$  were deemed significant.

### 3. Results

During a median follow-up of 12.4 years, 5648 incident dementia cases, including 1453

Alzheimer's disease and 649 vascular dementia cases, were diagnosed. The baseline

characteristics of 352,463 participants by incident dementia are displayed in **Table 1**.

Compared with individuals without incident dementia, the group with incident dementia were

older, with more males and poorer socioeconomical conditions, and had more unhealthy

behaviors and a higher prevalence of baseline gastrointestinal disorders (**Table 1**).

#### 3.1 Gastrointestinal Diseases and Dementia

Eight out of 14 gastrointestinal diseases showed associations with an increased risk of

dementia in the model adjusted for age and sex (**Table 2**). After adjustment for covariates and

correction for multiple testing, seven associations persisted in model 3 (**Table 2**). In detail, the

hazard ratio (HR) of dementia from largest to smallest was 2.21 (95% confidence interval [CI]

1.57, 3.31;  $P < 0.001$ ) for cirrhosis, 2.02 (95% CI 1.38, 2.98;  $P = 0.001$ ) for non-alcoholic fatty

liver disease, 1.68 (95% CI 1.53, 1.85;  $P < 0.001$ ) for gastritis and duodenitis, 1.62 (95% CI

1.46, 1.81;  $P < 0.001$ ) for irritable bowel syndrome, 1.48 (95% CI 1.30 1.68;  $P < 0.001$ ) for

peptic ulcer, 1.46 (95% CI 1.35, 1.58;  $P < 0.001$ ) for gastroesophageal reflux disease, and

1.26 (95% CI 1.13, 1.41  $P < 0.001$ ) for intestinal diverticular disease. No association was

observed for other gastrointestinal diseases (**Table 2**).

#### 3.2 Gastrointestinal Diseases and Dementia Subtypes

**Table 3** shows the associations of 14 gastrointestinal diseases with risk of incident

Alzheimer's disease and vascular dementia. For Alzheimer's disease, four associations

(irritable bowel syndrome, gastritis and duodenitis, non-alcoholic fatty liver disease, and

gastroesophageal reflux disease) were significant in the model 3 after FDR correction. For vascular dementia, five associations (gastritis and duodenitis, peptic ulcer, irritable bowel syndrome, gastroesophageal reflux disease, and intestinal diverticular disease) remained in the model 3 after correction for multiple testing. Gastrointestinal cancer showed a borderline positive association with vascular dementia (HR 1.86; 95% CI 1.07, 3.22;  $P = 0.064$ ), but not with Alzheimer's disease. No heterogeneity was detected in the associations of gastrointestinal diseases with risk of incident Alzheimer's disease and vascular dementia ( $P$ -heterogeneity  $> 0.05$ ).

The associations of gastrointestinal diseases differed with between early- and late-onset dementia (**Figure 1**). Compared to that for late-onset dementia, the associations for early-onset dementia appeared to be stronger with cirrhosis (HR 4.64; 95% CI 2.83, 7.60;  $P < 0.001$ ), irritable bowel syndrome (HR 2.47; 95% CI 2.09, 2.93;  $P < 0.001$ ), gastritis and duodenitis (HR 2.33; 95% CI 1.92, 2.82;  $P < 0.001$ ), gastroesophageal reflux disease (HR 2.23; 95% CI 1.91, 2.61;  $P < 0.001$ ), and peptic ulcer (HR 1.95; 95% CI 1.48, 2.58;  $P < 0.001$ ). Heterogeneity was detected for these associations between early- and late-onset dementia ( $P$ -heterogeneity  $< 0.05$ ).

### **3.3 Interactions with Sex, Educational Attainment, PRS, and APOE $\epsilon 4$**

There were no interactions between gastrointestinal diseases and sex or between gastrointestinal diseases and educational attainment ( $P$ -interaction  $> 0.05$ , **Supplementary Table 6**). PRS categories were significantly associated with the risk of dementia (**Supplementary Table 7**). We detected no interactions between gastrointestinal diseases and PRS or gastrointestinal diseases and APOE  $\epsilon 4$  carrying status ( $P$ -interaction  $> 0.05$ ,

**Figure S2 and Figure S3).**

### **3.4 Sensitivity Analyses**

The associations remained after accounting for competing risk of death (**Supplementary Table 8**), in a series of other sensitivity analyses (**Supplementary Table 9**), in the analysis including individuals who developed subsequent gastrointestinal diseases after baseline (**Supplementary Table 10**), and in the analysis excluding individuals with incident Parkinson's disease (**Supplementary Table 11**). Certain associations attenuated slightly albeit remained significant in the sensitivity analysis with further adjustment for regular PPIs use (**Supplementary Table 9**).

## **4. Discussion**

This large-scaled prospective cohort study found that seven gastrointestinal diseases were associated with an increased risk of dementia. Compared to individuals without gastrointestinal disorders, the risk of dementia increased from 26% for patients with intestinal diverticular disease to 121% for patients with cirrhosis. As for dementia subtypes, the associations were similar for Alzheimer's disease and vascular dementia. However, the associations of cirrhosis, irritable bowel syndrome, gastritis and duodenitis, gastroesophageal reflux disease, and peptic ulcer appeared to be more strongly associated with early-onset dementia compared to late-onset dementia. There were no interactions of gastrointestinal diseases with sex, education attainment, genetic risk, or *APOE ε4*.

The associations between different gastrointestinal disorders and dementia have been investigated in some previous studies mainly focusing on liver disease,<sup>12-14</sup> irritable bowel syndrome,<sup>27</sup> gastritis,<sup>28</sup> gastroesophageal reflux disease,<sup>29</sup> and diverticular disease<sup>30</sup>. Most

these studies found positive links between gastrointestinal diseases and the risk of dementia, which is in line with our findings based on a large-scaled cohort including more than 6000 incident cases. However, most of the above studies were based on the East Asian population<sup>11,27,30</sup> that owns a different patten of gastrointestinal diseases compared to other populations due to dietary habits and a high prevalence of *Helicobacter pylori* infection. Our data thus added novel information in support of the positive associations between a broad range of gastrointestinal diseases and dementia risk in the western world. Another study found that inflammatory bowel disease was associated with an increased risk of dementia, in particular early-onset type.<sup>11</sup> In our study, a borderline positive association was observed for Crohn's disease. Considering the wide confidence interval of the association, this nonsignificant result might be caused by an inadequate power due to a small number of cases. In addition, the associations of non-alcoholic fatty liver disease and cirrhosis with dementia were inconsistent between studies.<sup>12-14</sup> Even though our study detected the positive associations between two liver diseases and dementia, a Mendelian randomization analysis revealed a potential inverse effect of non-alcoholic fatty liver disease on dementia in a Finnish cohort.<sup>31</sup> The reason for this discrepancy is unclear but possibly related to competing risk of death. There are limited studies that examined the associations of gastritis and duodenitis, peptic ulcer, and gallbladder disease with dementia risk. Thus, our novel findings need further verification.

We examined the differences in the associations between gastrointestinal diseases with two common subtypes of dementia. No large differences were observed between the associations of Alzheimer's disease and vascular dementia with gastrointestinal diseases except for

gastrointestinal cancer. In detail, baseline gastrointestinal cancer is associated with an increased risk of vascular dementia but not with Alzheimer's disease. Even though previous studies found an inverse association of overall cancer diagnosis with the risk of dementia, which might be immune to diagnostic bias, competing risk bias, and confounding.<sup>32</sup> A higher risk of dementia was observed among colorectal cancer survivors<sup>33</sup>. Another interesting finding of our study in the stronger associations of certain gastrointestinal diseases with early-onset dementia compared to late-onset dementia. The possible reason for the differences may be that early-onset dementia is mainly caused by vascular comorbidities<sup>34</sup> that have a high prevalence rate among patients with hepatic,<sup>35</sup> intestinal,<sup>36</sup> and esophageal<sup>37</sup> dysfunction. These findings not only deepen the understanding in the etiological differences between early- and late-onset dementia but also may guide the secondary prevention for patients with different gastrointestinal conditions. We did not detect any interaction effects of sex, education attainment, genetic risk, or *APOE ε4*, which suggested that the associations between gastrointestinal disease and dementia risk might not differ between sub-populations stratified by these factors. Thus, the corresponding dementia prevention should be promoted in overall population.

The underlying pathways linking gastrointestinal diseases to dementia remain to be established; however, there are several plausible mechanisms that may explain the observed positive associations. The most important bridge of the associations is gut microbiome. The onset of gastrointestinal diseases that alters the normal function and microenvironment of the gastrointestinal tract may impact the diversity, components, and intensity of gut microbiota and the levels of their metabolites.<sup>38</sup> Animal studies have found that fecal microbiota

transplantation between Alzheimer's disease mouse and healthy controls changed the levels of amyloid and tau, memory function and neurogenesis.<sup>4,39</sup> In addition, the metabolites of gut microbiota, like bile acid and indole-3 propionate, have been identified as a potential mediator in the associations with cognitive impairment and nerve repair.<sup>6,7,40</sup> Treatments of gastrointestinal diseases, such as PPIs positively associated with dementia,<sup>15</sup> may also explain a part of the associations, which is partly supported by our data where most associations slightly attenuated with further adjustment for regular PPI use. *Helicobacter pylori* infection that was a frequent pathogen of gastric disease may also play a role;<sup>28</sup> however, this appears not to be a strong pathway since the association between *Helicobacter pylori* infection and dementia risk is undetermined<sup>41,42</sup> and the prevalence of *Helicobacter pylori* infection is quite low in the U.K. For vascular morbidity related gastrointestinal diseases, the increased burden of stroke may mediate the associations with in particular early-onset and vascular dementia. For gastritis and duodenitis and irritable bowel syndrome that have inflammation as a key pathogenic basis, cumulative chronic inflammation may increase the risk of dementia by facilitating neurocognitive changes and subsequent functional decline.<sup>43</sup>

The strengths of the study include a large sample size with a long follow-up time, a comprehensive investigation on a wide range of gastrointestinal conditions, and careful consideration and adjustment for confounders. Nonetheless, several limitations should be noted when interpreting our data. First, this is an observational cohort study, which cannot infer causality. However, we minimized possible biases from reverse causation and residual confounding by excluding incident cases diagnosed during the first year of follow-up and adjusted for vital risk factors for dementia. Second, there might be misclassifications of



gastrointestinal diseases even though the used diagnostic codes have been found to be valid

<sup>17</sup>. Due to the prospective design of the study, these misclassifications should be

nondifferential and therefore attenuated the associations in a conservative way. Third, except

for PPIs, we did not take other treatments for gastrointestinal disorders into consideration.

Forth, we might have had insufficient power to detect weak associations owing to few cases

for infrequent gastrointestinal diseases. Fifth, a genome-wide cross-trait analysis revealed

shared genetic architecture between Alzheimer's disease and gastrointestinal diseases.<sup>44</sup>

Thus, we could not completely rule out the possibility that the observed associations were

caused by shared genetic risk factors even though our results were robust in the analysis with

the additional adjustment for the family history of dementia and PRS.

In summary, this cohort study found associations of seven gastrointestinal diseases with an

increased risk of incident dementia. The associations appeared to be stronger for early-onset

dementia compared to late-onset dementia. Our findings provide novel understandings about

the etiology of early- and late-onset dementia and imply the great importance of dementia

prevention among patients with gastrointestinal diseases.

## **Declaration of competing interest**

The authors declare that they have no competing interests

## **Acknowledgments**

We are much obliged to the administer team of the UK Biobank as well as all the participants.

## **Funding information**

SCL is supported by funding from the Swedish Research Council (Vetenskapsrådet; Grant Number 2019-00977) and the Swedish Research Council for Health, Working Life and Welfare (Forte; 2018-00123). XL is supported by the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (grant no. 82204019).

## **Ethics approval and consent to participate**

The ethical approval was granted for the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 21/NW/0157). All participants provided informed consent through electronic signature at baseline assessment. This study was conducted with the UK Biobank Resource under application number 66354.

## **Availability of data and materials**

The datasets analysed during the current study are available in a public, open access repository (<https://www.ukbiobank.ac.uk/>).

## **CRedit authorship contribution statement**

All authors read and approved the final manuscript.

Shuai Yuan (Conceptualization: Supporting; Methodology: Equal; Writing - review & editing: Leading)

Lintao Dan (Conceptualization: Supporting; Methodology: Equal; Formal analysis: Leading; Writing - original draft: Supporting; and Writing - review & editing: Equal)

Yao Zhang (Conceptualization: Supporting; Writing - original draft: Equal; Writing - review & editing: Equal)

Jing Wu (Conceptualization: Supporting; Methodology: Supporting; Writing - review & editing: Equal)

Jianhui Zhao (Conceptualization: Supporting; Writing - review & editing: Equal)

Jie Chen (Conceptualization: Leading; Methodology: Equal; Formal analysis: Supporting; Writing - original draft: Supporting; Writing - review & editing: Equal)

Xue Li (Conceptualization: Leading; Data curation: Equal; and Funding acquisition: Leading; Writing - review & editing: Equal)

Miia Kivipelto (Conceptualization: Supporting; Writing - review & editing: Equal)

Susanna C. Larsson (Conceptualization: Equal; Data curation: Equal; and Funding acquisition: Equal; and Writing - review & editing: Leading)

## References

1. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. Aug 8 2020;396(10248):413-446.  
doi:10.1016/s0140-6736(20)30367-6
2. Oh ES, Rabins PV. Dementia. *Ann Intern Med*. Sep 3 2019;171(5):ltc33-itc48.  
doi:10.7326/aitc201909030
3. Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. *J Clin Invest*. Mar 2 2015;125(3):926-38. doi:10.1172/jci76304
4. Kim N, Jeon SH, Ju IG, et al. Transplantation of gut microbiota derived from Alzheimer's disease mouse model impairs memory function and neurogenesis in C57BL/6 mice. *Brain Behav Immun*. Nov 2021;98:357-365. doi:10.1016/j.bbi.2021.09.002
5. Liu P, Wu L, Peng G, et al. Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive impairment and health in a Chinese cohort. *Brain Behav Immun*. Aug 2019;80:633-643. doi:10.1016/j.bbi.2019.05.008
6. MahmoudianDehkordi S, Arnold M, Nho K, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimers Dement*. Jan 2019;15(1):76-92. doi:10.1016/j.jalz.2018.07.217
7. Nho K, Kueider-Paisley A, MahmoudianDehkordi S, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. *Alzheimers Dement*. Feb 2019;15(2):232-244. doi:10.1016/j.jalz.2018.08.012
8. Connell E, Le Gall G, Pontifex MG, et al. Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia. *Mol Neurodegener*. Jun 17 2022;17(1):43.  
doi:10.1186/s13024-022-00548-6

9. Ni J, Wu GD, Albenberg L, Tomov VT. Gut microbiota and IBD: causation or correlation?

*Nat Rev Gastroenterol Hepatol.* Oct 2017;14(10):573-584. doi:10.1038/nrgastro.2017.88

10. Nardone G, Compare D, Rocco A. A microbiota-centric view of diseases of the upper

gastrointestinal tract. *Lancet Gastroenterol Hepatol.* Apr 2017;2(4):298-312.

doi:10.1016/s2468-1253(16)30108-x

11. Zhang B, Wang HE, Bai YM, et al. Inflammatory bowel disease is associated with higher

dementia risk: a nationwide longitudinal study. *Gut.* Jan 2021;70(1):85-91. doi:10.1136/gutjnl-

2020-320789

12. Shang Y, Widman L, Hagström H. Nonalcoholic Fatty Liver Disease and Risk of

Dementia: A Population-Based Cohort Study. *Neurology.* Aug 9 2022;99(6):e574-e582.

doi:10.1212/wnl.0000000000200853

13. Newton JL, Hollingsworth KG, Taylor R, et al. Cognitive impairment in primary biliary

cirrhosis: symptom impact and potential etiology. *Hepatology.* Aug 2008;48(2):541-9.

doi:10.1002/hep.22371

14. Xiao T, van Kleef L, Ikram MK, De Kneeght R, Ikram MA. Association of Nonalcoholic Fatty

Liver Disease and Fibrosis With Incident Dementia and Cognition: The Rotterdam Study.

*Neurology.* Aug 9 2022;99(6):e565-e573. doi:10.1212/wnl.0000000000200770

15. Gomm W, von Holt K, Thomé F, et al. Association of Proton Pump Inhibitors With Risk of

Dementia: A Pharmacoepidemiological Claims Data Analysis. *JAMA Neurol.* Apr

2016;73(4):410-6. doi:10.1001/jamaneurol.2015.4791

16. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for

identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.*

Mar 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

17. Commission A. Improving data quality in the NHS: annual report on the PbR assurance

programme. Accessed August 1, 2022. [https://www.bl.uk/collection-items/improving-data-](https://www.bl.uk/collection-items/improving-data-quality-in-the-nhs-annual-report-on-the-pbr-assurance-programme)

[quality-in-the-nhs-annual-report-on-the-pbr-assurance-programme](https://www.bl.uk/collection-items/improving-data-quality-in-the-nhs-annual-report-on-the-pbr-assurance-programme)

18. Calvin CM, Wilkinson T, Starr JM, et al. Predicting incident dementia 3-8 years after brief cognitive tests in the UK Biobank prospective study of 500,000 people. *Alzheimers Dement*.

Dec 2019;15(12):1546-1557. doi:10.1016/j.jalz.2019.07.014

19. Elahi FM, Miller BL. A clinicopathological approach to the diagnosis of dementia. *Nat Rev Neurol*. Aug 2017;13(8):457-476. doi:10.1038/nrneurol.2017.96

20. Ebenau JL, van der Lee SJ, Hulsman M, et al. Risk of dementia in APOE  $\epsilon$ 4 carriers is mitigated by a polygenic risk score. *Alzheimers Dement (Amst)*. 2021;13(1):e12229.

doi:10.1002/dad2.12229

21. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A $\beta$ , tau, immunity and lipid processing. *Nat Genet*. Mar 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2

22. Sims R, van der Lee SJ, Naj AC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet*. Sep 2017;49(9):1373-1384. doi:10.1038/ng.3916

23. de Rojas I, Moreno-Grau S, Tesi N, et al. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nat Commun*. Jun 7 2021;12(1):3417.

doi:10.1038/s41467-021-22491-8

24. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed

- Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet.* Mar 2019;51(3):414-430. doi:10.1038/s41588-019-0358-2
25. Lourida I, Hannon E, Littlejohns TJ, et al. Association of Lifestyle and Genetic Risk With Incidence of Dementia. *Jama.* Aug 6 2019;322(5):430-437. doi:10.1001/jama.2019.9879
26. Wang M, Spiegelman D, Kuchiba A, et al. Statistical methods for studying disease subtype heterogeneity. *Stat Med.* Feb 28 2016;35(5):782-800. doi:10.1002/sim.6793
27. Chen CH, Lin CL, Kao CH. Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study. *PLoS One.* 2016;11(1):e0144589. doi:10.1371/journal.pone.0144589
28. Kountouras J, Gavalas E, Boziki M, Zavos C. Helicobacter pylori may be involved in cognitive impairment and dementia development through induction of atrophic gastritis, vitamin B-12 folate deficiency, and hyperhomocysteinemia sequence. *Am J Clin Nutr.* Sep 2007;86(3):805-6; author reply 806-7. doi:10.1093/ajcn/86.3.805
29. Gau SY, Lai JN, Yip HT, Wu MC, Wei JC. Higher Dementia Risk in People With Gastroesophageal Reflux Disease: A Real-World Evidence. *Front Aging Neurosci.* 2022;14:830729. doi:10.3389/fnagi.2022.830729
30. Peng YC, Lin CL, Yeh HZ, Tung CF, Chang CS, Kao CH. Diverticular disease and additional comorbidities associated with increased risk of dementia. *J Gastroenterol Hepatol.* Nov 2016;31(11):1816-1822. doi:10.1111/jgh.13389
31. Liu Z, Suo C, Fan H, Zhang T, Jin L, Chen X. Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases. *Metabolism.* Oct 2022;135:155270.

doi:10.1016/j.metabol.2022.155270

32. Ospina-Romero M, Glymour MM, Hayes-Larson E, et al. Association Between Alzheimer Disease and Cancer With Evaluation of Study Biases: A Systematic Review and Meta-analysis. *JAMA Netw Open*. Nov 2 2020;3(11):e2025515.

doi:10.1001/jamanetworkopen.2020.25515

33. Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. *Br J Cancer*. Nov 8 2011;105 Suppl 1(Suppl 1):S29-37. doi:10.1038/bjc.2011.420

34. Heath CA, Mercer SW, Guthrie B. Vascular comorbidities in younger people with dementia: a cross-sectional population-based study of 616 245 middle-aged people in Scotland. *J Neurol Neurosurg Psychiatry*. Sep 2015;86(9):959-64. doi:10.1136/jnnp-2014-309033

35. Jepsen P. Comorbidity in cirrhosis. *World J Gastroenterol*. Jun 21 2014;20(23):7223-30. doi:10.3748/wjg.v20.i23.7223

36. Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S. Comorbidities in inflammatory bowel disease: a call for action. *Lancet Gastroenterol Hepatol*. Aug 2019;4(8):643-654. doi:10.1016/s2468-1253(19)30173-6

37. Sun X, Chen L, Zheng L. A Mendelian Randomization Study to Assess the Genetic Liability of Gastroesophageal Reflux Disease for Cardiovascular Diseases and Risk Factors. *Hum Mol Genet*. Jul 21 2022;doi:10.1093/hmg/ddac162

38. de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. *Gut*. May 2022;71(5):1020-1032. doi:10.1136/gutjnl-2021-326789

39. Kim MS, Kim Y, Choi H, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. *Gut*. Feb 2020;69(2):283-294.  
doi:10.1136/gutjnl-2018-317431
40. Serger E, Luengo-Gutierrez L, Chadwick JS, et al. The gut metabolite indole-3 propionate promotes nerve regeneration and repair. *Nature*. Jul 2022;607(7919):585-592.  
doi:10.1038/s41586-022-04884-x
41. Beydoun MA, Beydoun HA, Elbejjani M, Dore GA, Zonderman AB. Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys. *Alzheimers Dement*. Sep 2018;14(9):1148-1158.  
doi:10.1016/j.jalz.2018.04.009
42. Fani L, Wolters FJ, Ikram MK, et al. Helicobacter pylori and the risk of dementia: A population-based study. *Alzheimers Dement*. Oct 2018;14(10):1377-1382.  
doi:10.1016/j.jalz.2018.05.005
43. Walker KA, Gottesman RF, Wu A, et al. Systemic inflammation during midlife and cognitive change over 20 years: The ARIC Study. *Neurology*. Mar 12 2019;92(11):e1256-e1267. doi:10.1212/wnl.00000000000007094
44. Adewuyi EO, O'Brien EK, Nyholt DR, Porter T, Laws SM. A large-scale genome-wide cross-trait analysis reveals shared genetic architecture between Alzheimer's disease and gastrointestinal tract disorders. *Commun Biol*. Jul 18 2022;5(1):691. doi:10.1038/s42003-022-03607-2



**Table 1. Baseline characteristics by incident dementia**

<b>Characteristic <sup>a</sup></b>	<b>Without incident dementia (n = 346,815)</b>	<b>Incident dementia (n = 5648)</b>	<b>P</b>
Age at baseline in years	55.78 (8.14)	61.57 (7.43)	<0.001
Sex (%)			<0.001
Female	187355 (54.0)	2829 (50.1)	
Male	159460 (46.0)	2819 (49.9)	
Townsend deprivation index	-1.39 (3.05)	-0.96 (3.29)	<0.001
Educational attainment (%)			<0.001
Below college degree	221820 (64.7)	4162 (75.3)	
College degree	120853 (35.3)	1366 (24.7)	
Physical activity (%)			<0.001
Inadequate	100788 (29.1)	1980 (35.1)	
Adequate	246027 (70.9)	3668 (64.9)	
Smoking status (%)			<0.001
Never smoked	196102 (56.8)	2742 (48.9)	
Previous or current smokers	149108 (43.2)	2863 (51.1)	
Alcohol consumption (%)			<0.001
None to moderate	70238 (20.3)	1004 (17.8)	
Heavy	275862 (79.7)	4624 (82.2)	
BMI in kg/m <sup>2</sup>	27.11 (4.65)	27.54 (4.93)	<0.001
Healthy diet (%)			0.366
Unhealthy	91864 (27.8)	1396 (27.2)	
Healthy	238480 (72.2)	3731 (72.8)	
APOE ε4 carrier (%)	142832 (41.2)	3144 (55.7)	<0.001
Polygenic risk score category (%)			<0.001
Low	69565 (20.1)	928 (16.4)	
Intermediate	208170 (60.0)	3307 (58.6)	
High	69080 (19.9)	1413 (25.0)	
Baseline depression (%)	73157 (21.1)	1517 (26.9)	<0.001
Baseline hypertension (%)	236073 (68.1)	4360 (77.3)	<0.001
Baseline stroke (%)	4179 (1.2)	230 (4.1)	<0.001
Family history of dementia (%)	36971 (10.7)	920 (16.3)	<0.001
Baseline gastroesophageal reflux disease (%)	24008 (6.9)	685 (12.1)	<0.001
Baseline gastritis and duodenitis (%)	13708 (4.0)	476 (8.4)	<0.001
Baseline celiac disease (%)	1620 (0.5)	39 (0.7)	0.020
Baseline Crohn's disease (%)	1239 (0.4)	29 (0.5)	0.067
Baseline ulcerative colitis (%)	2378 (0.7)	45 (0.8)	0.357
Baseline intestinal diverticular disease (%)	10049 (2.9)	336 (5.9)	<0.001
Baseline irritable bowel syndrome (%)	14496 (4.2)	349 (6.2)	<0.001
Baseline peptic ulcer (%)	7345 (2.1)	250 (4.4)	<0.001
Baseline pancreatitis (%)	944 (0.3)	26 (0.5)	0.011
Baseline gallbladder disease (%)	10619 (3.1)	249 (4.4)	<0.001
Baseline non-alcoholic fatty liver disease (%)	708 (0.2)	26 (0.5)	<0.001
Baseline cirrhosis (%)	838 (0.2)	33 (0.6)	<0.001
Baseline appendicitis (%)	4856 (1.4)	67 (1.2)	0.193
Baseline overall gastrointestinal cancer (%)	1935 (0.6)	53 (0.9)	<0.001

BMI, body mass index. Continuous variables were expressed in mean (standard deviation, SD) and categorical variables in number (%). <sup>a</sup> Chi-squared test and t-test were used to compare the characteristics of those with and without incident dementia as appropriate.

**Table 2. Associations between baseline gastrointestinal diseases and risk of incident dementia**

Case/person-year		Model 1			Model 2			Model 3		
		HR (95% CI) <sup>a</sup>	P	Q value	HR (95% CI) <sup>b</sup>	P	Q value	HR (95% CI) <sup>c</sup>	P	Q value <sup>d</sup>
<b>Gastroesophageal reflux disease</b>										
Without	4963/3,843,038	Ref			Ref			Ref		
With	685/282,924	1.53 (1.41, 1.66)	<0.001	<0.001	1.46 (1.35, 1.58)	<0.001	<0.001	1.46 (1.35, 1.58)	<0.001	<0.001
<b>Gastritis and duodenitis</b>										
Without	5172/3,965,389	Ref			Ref			Ref		
With	476/160,573	1.82 (1.65, 2.00)	<0.001	<0.001	1.68 (1.53, 1.85)	<0.001	<0.001	1.68 (1.53, 1.85)	<0.001	<0.001
<b>Celiac disease</b>										
Without	5609/4,106,653	Ref			Ref			Ref		
With	39/19,309	1.34 (0.98, 1.83)	0.071	0.099	1.35 (0.98, 1.84)	0.065	0.101	1.36 (0.99, 1.86)	0.059	0.097
<b>Crohn's disease</b>										
Without	5619/4,111,432	Ref			Ref			Ref		
With	29/14,530	1.48 (1.03, 2.13)	0.036	0.056	1.39 (0.97, 2.01)	0.076	0.106	1.40 (0.97, 2.02)	0.069	0.097
<b>Ulcerative colitis</b>										
Without	5603/4,097,823	Ref			Ref			Ref		
With	45/28,140	1.11 (0.83, 1.49)	0.478	0.478	1.06 (0.79, 1.42)	0.689	0.689	1.06 (0.79, 1.42)	0.694	0.694
<b>Intestinal diverticular disease</b>										
Without	5312/4,007,355	Ref			Ref			Ref		
With	336/118,607	1.32 (1.18, 1.47)	<0.001	<0.001	1.27 (1.13, 1.41)	<0.001	<0.001	1.26 (1.13, 1.41)	<0.001	<0.001
<b>Irritable bowel syndrome</b>										
Without	5299/3,953,265	Ref			Ref			Ref		
With	349/172,698	1.64 (1.47, 1.83)	<0.001	<0.001	1.63 (1.46, 1.81)	<0.001	<0.001	1.62 (1.46, 1.81)	<0.001	<0.001
<b>Peptic ulcer</b>										

Without	5398/4,039,084	Ref			Ref			Ref		
With	250/86,879	1.61 (1.42, 1.83)	<0.001	<0.001	1.47 (1.30, 1.68)	<0.001	<0.001	1.48 (1.30, 1.68)	<0.001	<0.001
<b>Pancreatitis</b>										
Without	5622/4,115,013	Ref			Ref			Ref		
With	26/10,949	1.40 (0.95, 2.06)	0.086	0.109	1.31 (0.89, 1.92)	0.176	0.224	1.32 (0.90, 1.94)	0.16	0.204
<b>Gallbladder disease</b>										
Without	5399/4,000,697	Ref			Ref			Ref		
With	249/125,266	1.19 (1.05, 1.35)	0.008	0.014	1.13 (0.99, 1.28)	0.063	0.101	1.13 (0.99, 1.28)	0.069	0.097
<b>Non-alcoholic fatty liver disease</b>										
Without	5622/4,117,654	Ref			Ref			Ref		
With	26/8,308	2.22 (1.51, 3.26)	<0.001	<0.001	2.02 (1.37, 2.97)	<0.001	0.001	2.02 (1.38, 2.98)	<0.001	0.001
<b>Cirrhosis</b>										
Without	5615/4,116,513	Ref			Ref			Ref		
With	33/9,449	2.36 (1.68, 3.33)	<0.001	<0.001	2.23 (1.58, 3.14)	<0.001	<0.001	2.21 (1.57, 3.11)	<0.001	<0.001
<b>Appendicitis</b>										
Without	5581/4,070,389									
With	67/55,574	0.88 (0.69, 1.12)	0.288	0.336	0.86 (0.68, 1.09)	0.22	0.257	0.86 (0.68, 1.09)	0.219	0.256
<b>Overall gastrointestinal cancer</b>										
Without	5595/4,105,033									
With	53/20,930	1.13 (0.86, 1.48)	0.387	0.417	1.09 (0.83, 1.43)	0.541	0.582	1.09 (0.83, 1.43)	0.538	0.58

CI, confidence interval; HR, hazard ratio.

<sup>a</sup> adjusted for the age and sex.

<sup>b</sup> adjusted for age, sex, Townsend deprivation index, educational attainment, BMI, physical activity, diet, smoking status, alcohol consumption, baseline hypertension, and baseline stroke

<sup>c</sup> adjusted for age, sex, Townsend deprivation index, educational attainment, BMI, physical activity, diet, smoking status, alcohol consumption, baseline hypertension, baseline stroke, and polygenic risk scores.

<sup>d</sup> Two-sided FDR-adjusted P value (Q value) < 0.05 were considered significant.

**Table 3. Associations between gastrointestinal diseases and risk of incident Alzheimer's disease and vascular dementia**

	Alzheimer's disease				Vascular dementia				P-heterogeneity
	Case/person-year	HR (95% CI) <sup>a</sup>	P	Q <sup>b</sup>	Case/person-year	HR (95% CI) <sup>a</sup>	P	Q <sup>b</sup>	
<b>Gastroesophageal reflux disease</b>									0.226
Without	1282/3,857,645	Ref			557/3,857,645	Ref			
With	171/285,279	1.30 (1.11, 1.53)	0.001	0.009	92/285,279	1.54 (1.23, 1.92)	<0.001	0.001	
<b>Gastritis and duodenitis</b>									0.454
Without	1337/3,980,771	Ref			585/3,980,771	Ref			
With	116/162,153	1.47 (1.22, 1.78)	<0.001	0.001	64/162,153	1.66 (1.28, 2.15)	<0.001	0.001	
<b>Celiac disease</b>									0.106
Without	1440/4,123,458	Ref			648/4,123,458	Ref			
With	13/19,466	1.64 (0.95, 2.84)	0.074	0.130	1/19,466	0.30 (0.04, 2.13)	0.228	0.400	
<b>Crohn's disease</b>									NA
Without	1445/4,128,332	Ref			649/4,128,332	Ref			
With	8/14,592	1.54 (0.77, 3.08)	0.224	0.314	0/14,592	NA	NA	NA	
<b>Ulcerative colitis</b>									0.898
Without	1444/4,114,682	Ref			645/4,114,682	Ref			
With	9/28,242	0.81 (0.42, 1.57)	0.540	0.587	4/28,242	0.75 (0.28, 2.01)	0.570	0.726	
<b>Intestinal diverticular disease</b>									0.277
Without	1355/4,023,486	Ref			594/4,023,486	Ref			
With	98/119,438	1.23 (1.00, 1.51)	0.050	0.119	55/119,438	1.49 (1.13, 1.97)	0.005	0.014	
<b>Irritable bowel syndrome</b>									0.301
Without	1377/3,968,630	Ref			611/3,968,630	Ref			
With	76/174,294	1.39 (1.10, 1.75)	0.006	0.026	38/174,294	1.72 (1.23, 2.39)	0.001	0.005	
<b>Peptic ulcer</b>									0.125
Without	1392/4,055,330	Ref			606/4,055,330	Ref			
With	61/87,594	1.29 (1.00, 1.67)	0.051	0.119	43/87,594	1.77 (1.30, 2.42)	<0.001	0.002	
<b>Pancreatitis</b>									0.523
Without	1443/4,131,905	Ref			646/4,131,905	Ref			

With	10/11,019	1.80 (0.97, 3.36)	0.064	0.127	3/11,019	1.18 (0.38, 3.67)	0.775	0.898	
<b>Gallbladder disease</b>									
Without	1397/4,016,869	Ref			616/4,016,869	Ref			0.160
With	56/126,055	0.88 (0.67, 1.15)	0.351	0.447	33/126,055	1.21 (0.85, 1.72)	0.288	0.403	
<b>Non-alcoholic fatty liver disease</b>									
Without	1445/4,134,532	Ref			646/4,134,532	Ref			0.726
With	8/8,392	2.41 (1.20, 4.82)	0.013	0.047	3/8,392	1.90 (0.61, 5.91)	0.268	0.403	
<b>Cirrhosis</b>									
Without	1446/4,133,368	Ref			647/4,133,368	Ref			0.589
With	7/9,556	1.79 (0.85, 3.77)	0.124	0.192	2/9,556	1.16 (0.29, 4.65)	0.834	0.898	
<b>Appendicitis</b>									
Without	1433/4,087,141	Ref			645/4,087,141	Ref			0.110
With	20/55,783	1.07 (0.69, 1.66)	0.775	0.775	4/55,783	0.45 (0.17, 1.19)	0.107	0.214	
<b>Overall gastrointestinal cancer</b>									
Without	1441/4,121,906	Ref			636/4,121,906	Ref			0.053
With	12/21,018	0.84 (0.48, 1.48)	0.545	0.587	13/21,018	1.86 (1.07, 3.22)	0.027	0.064	

CI, confidence interval; HR, hazard ratio; NA, not applicable.

<sup>a</sup> Associations were derived from model 3 adjusted for age, sex, Townsend deprivation index, educational attainment, BMI, physical activity, diet, smoking status, alcohol consumption, baseline hypertension, and baseline stroke, and polygenic risk score.

<sup>b</sup> Two-sided FDR-adjusted P value (Q value) < 0.05 were considered significant.

**Figure 1. Associations between baseline gastrointestinal diseases and risk of incident dementia by onset age.** CI, confidence interval; HR, hazard ratio. Estimates were adjusted for age, sex, Townsend deprivation index, educational attainment, BMI, physical activity, diet, smoking status, alcohol consumption, baseline hypertension, baseline stroke, and polygenic risk score. \* Representing a significant association after FDR correction for multiple comparison. *P* for heterogeneity was two-sided FDR-adjusted.



# STROBE Statement—Checklist of items that should be included in reports of cohort studies

\*Give information separately for exposed and unexposed groups.

	Item No	Recommendation	Page No.
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4-5
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7-10, Fig. S1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-10
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	7-8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	8-10
		(c) Explain how missing data were addressed	8-10
		(d) If applicable, explain how loss to follow-up was addressed	8-10
		(e) Describe any sensitivity analyses	8-10
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Fig. S1
		(b) Give reasons for non-participation at each stage	7-9
		(c) Consider use of a flow diagram	Fig. S1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	11
		(b) Indicate number of participants with missing data for each variable of interest	Table 1; Fig. S1
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12, Table 2
		(b) Report category boundaries when continuous variables were categorized	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	12-13

<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	13-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	15-17
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	16-17
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	18

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

